Elanco Animal Health (NYSE:ELAN – Get Rating) updated its FY 2022 earnings guidance on Friday. The company provided earnings per share guidance of $1.01-$1.07 for the period, compared to the consensus earnings per share estimate of $1.05. The company issued revenue guidance of $4.38 billion-$4.43 billion, compared to the consensus revenue estimate of $4.41 billion.
Analyst Upgrades and Downgrades
→ Is This The End of Capitalism? (From Porter & Company)
A number of brokerages recently weighed in on ELAN. The Goldman Sachs Group reduced their price objective on Elanco Animal Health from $19.00 to $12.00 and set a sell rating on the stock in a research report on Wednesday, November 9th. TheStreet downgraded Elanco Animal Health from a c- rating to a d+ rating in a report on Tuesday, October 4th. JPMorgan Chase & Co. decreased their price target on Elanco Animal Health from $24.00 to $20.00 and set a neutral rating for the company in a research note on Monday, October 17th. Piper Sandler decreased their target price on shares of Elanco Animal Health from $21.00 to $15.00 and set a neutral rating for the company in a research report on Monday, November 14th. Finally, William Blair restated a market perform rating on shares of Elanco Animal Health in a research report on Tuesday, November 8th. One analyst has rated the stock with a sell rating and six have assigned a hold rating to the company’s stock. According to data from MarketBeat, Elanco Animal Health has an average rating of Hold and a consensus price target of $17.83.
Elanco Animal Health Price Performance
ELAN stock opened at $13.88 on Friday. The stock’s 50 day simple moving average is $12.55 and its 200 day simple moving average is $14.49. The company has a quick ratio of 1.12, a current ratio of 1.96 and a debt-to-equity ratio of 0.82. Elanco Animal Health has a fifty-two week low of $11.18 and a fifty-two week high of $29.66.
Elanco Animal Health (NYSE:ELAN – Get Rating) last issued its earnings results on Tuesday, November 8th. The company reported $0.20 earnings per share for the quarter, topping analysts’ consensus estimates of $0.16 by $0.04. The company had revenue of $1.03 billion for the quarter, compared to analyst estimates of $1.03 billion. Elanco Animal Health had a positive return on equity of 7.65% and a negative net margin of 2.64%. Equities research analysts forecast that Elanco Animal Health will post 1.04 EPS for the current fiscal year.
Insider Transactions at Elanco Animal Health
In related news, Director John P. Bilbrey acquired 7,500 shares of the stock in a transaction dated Friday, November 11th. The stock was purchased at an average cost of $13.24 per share, with a total value of $99,300.00. Following the completion of the purchase, the director now directly owns 41,722 shares in the company, valued at approximately $552,399.28. The purchase was disclosed in a filing with the SEC, which is available through this hyperlink. 6.40% of the stock is currently owned by insiders.
Hedge Funds Weigh In On Elanco Animal Health
A number of hedge funds have recently bought and sold shares of the company. KB Financial Partners LLC increased its position in shares of Elanco Animal Health by 8.2% during the first quarter. KB Financial Partners LLC now owns 8,709 shares of the company’s stock valued at $227,000 after acquiring an additional 658 shares during the last quarter. Baird Financial Group Inc. increased its position in shares of Elanco Animal Health by 1.8% during the 3rd quarter. Baird Financial Group Inc. now owns 47,406 shares of the company’s stock valued at $589,000 after purchasing an additional 843 shares during the last quarter. Captrust Financial Advisors raised its stake in shares of Elanco Animal Health by 57.0% during the 1st quarter. Captrust Financial Advisors now owns 2,690 shares of the company’s stock worth $70,000 after purchasing an additional 977 shares during the period. Neuberger Berman Group LLC raised its stake in shares of Elanco Animal Health by 14.9% during the 1st quarter. Neuberger Berman Group LLC now owns 11,071 shares of the company’s stock worth $289,000 after purchasing an additional 1,432 shares during the period. Finally, Guggenheim Capital LLC boosted its holdings in shares of Elanco Animal Health by 12.5% in the 3rd quarter. Guggenheim Capital LLC now owns 13,510 shares of the company’s stock worth $168,000 after buying an additional 1,506 shares during the last quarter.
Elanco Animal Health Company Profile
Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Elanco Animal Health, you’ll want to hear this.
MarketBeat keeps track of Wall Street’s top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on… and Elanco Animal Health wasn’t on the list.
While Elanco Animal Health currently has a “Hold” rating among analysts, top-rated analysts believe these five stocks are better buys.